RxDoctor Payments Data

Keirsten Eagles

Optometrist · Silverton, ORNPI 1881893626

Payments from drug & device makers

$968in general payments, 2019–2025

Across 35 payments — averaging $27.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kala Pharmaceuticals, Inc.$158
  • Tarsus Pharmaceuticals, Inc.$125
  • Bausch & Lomb Americas Inc.$85
  • Sun Pharmaceutical Industries Inc.$74
  • Coopervision Inc.$73
  • Oyster Point Pharma, Inc.$63
  • plus $389 from 9 others

What the payments were for

  • Food & beverage$86790%
  • Education$243%
  • Gifts$768%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$968 in reported general payments places this provider in the 70th percentile of 684 optometrist providers in Oregon.

See all optometrist providers in Oregon

Medicare billing

Part B allowed, 2024
$34,530
Medicare patients
100
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine48$47,492
XdemvyLotilaner13$25,157
LumiganBimatoprost26$7,636
Cyclosporine11$3,539
Brimonidine Tartrate28$1,989
Latanoprost133$1,389
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat25$430
Timolol Maleate23$221
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha17$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$53$55,12774 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$125$25,15713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 684 optometrist providers in Oregon.

Other optometrist in Silverton

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →